Business Wire

AÉMA-GROUPE

30.9.2021 14:15:05 CEST | Business Wire | Press release

Share
Aéma Groupe Concludes the Acquisition of Aviva France, Becoming One of the Top 5 French Insurers

On 30 September 2021, Aéma Groupe acquired Aviva France, after obtaining the necessary authorisations from the regulatory authorities. This large-scale operation places Aéma Groupe in the 5th position of the French insurance industry. It concretises the original ambition of Macif and Aésio Mutuelle, founders of Aéma Groupe, to build a leading mutual insurance group that now protects over 11 million French people.

‘The creation of Aéma Groupe was the culmination of the ambition of two companies, Aésio Mutuelle and Macif, to join forces to build a large-scale mutual insurance group capable of offering the broadest possible protection to its policyholders, both today and tomorrow. The acquisition of Aviva France is the first phase in this process. This transaction, which was completed in less than a year and ahead of schedule, demonstrates our ability to build a strong and innovative player that meets the growing needs of society as a whole’. - Adrien Couret - Managing Director of Aéma Groupe.

An acquisition that confirms the relevance of the Aéma Groupe model

Thanks to its economic significance and strategic importance, this transaction brings Aviva France under the French mutual insurance umbrella. Aéma Groupe thereby demonstrates its ability to expand and serve a wider range of policyholders (individuals, professionals, self-employed persons, companies) with a comprehensive range of solutions. This multi-brand, multi-network, multi-business group is strengthening its positions in all areas of insurance thanks to its complementary expertise. As a resolutely mutualist group, it will also make the voice of its members and customers heard in the public debate on social issues relating to protection and retirement.

‘We are very proud to welcome this fine company as the third pillar of Aéma Groupe, alongside Macif and Aésio. With Aviva France, we are creating a leading French mutual insurance group. From now on, Aviva France, supported by its 4,500 employees, will keep growing within our common structure. It will accomplish this while retaining its identity and its specific characteristics, with the same determination to provide increasingly relevant and sustainable insurance solutions to its 3 million policyholders, including the 760,000 members of AFER’. - Pascal Michard , Chairperson of Aéma Groupe.

New management for Aviva France

Following the acquisition, Aviva France has formed its new board of directors, which has appointed Jean-Philippe Dogneton as Chairperson and Philippe-Michel Labrosse as Chief Executive Officer of Aviva France.

‘In addition to enriching our diversity, the arrival of Aviva France within our group will enhance our diversity and gives us new responsibilities vis-à-vis the policyholders, the members and the clients we deal with on a daily basis. This acquisition will enhance the synergies of skills and expertise and the mutual know-how to enrich our offers and services. We are extremely proud and happy to welcome the Aviva France teams who share our values of solidarity and commitment’. - Jean-Philippe Dogneton , Assistant Managing Director of Aéma Groupe, Managing Director of Macif and new Chairperson of Aviva France

I would like to thank the Board of Directors of Aviva France for trusting me to anchor the company to Aéma Groupe, its new parent company, and to keep it on the path to success with the support of all its employees, networks and partners’. Philippe-Michel Labrosse – Managing Director of Aviva France.

Aviva France will be rebranded with a gradual roll-out.

This acquisition involved Lazard as lead M&A advisor, Credit Suisse as financing and M&A advisor, White & Case LLP as legal advisor, Kearney for strategy, EY for accounting and financial analysis, Prim'Act for actuarial services, and Fromont Briens for employment law.

–––––––––––––––––––––––––––––––––––––––––––––––––

Key figures:

  • 14.5 billion euro in turnover;
  • 18,000 employees;
  • 11 million policyholders;
  • Property & Casualty: 5 billion euro in premium income;
  • Health & Personal Protection: 3 billion euro in premium income;
  • Life business: 6.5 billion euro in premium income;
  • Assets under management: 195 billion euro.

Leading positions in the business lines:

  • 5th largest insurance company in France;
  • 2nd largest player in home and car insurance;
  • 3rd largest mutual group in individual and group health;
  • 5th largest player in life insurance;
  • 6th largest player in asset management.

About Aéma Groupe
Aéma is the mutual insurance group formed by the merger of Aésio Mutuelle and Macif.
With more than 11 million policyholders, it employs 18,000 people
and generates a turnover of 14.5 billion euros in France.
Aéma Groupe envisions a fairer and more humane world every day by making foresight a central part of the relationship with its members, policyholders and corporate clients.
Find out more: aemagroupe.fr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release

Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2

Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release

Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar

Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release

Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat

Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 19:09:00 CET | Press release

PriceRunner v. Google: Sweden’s Largest-Ever Civil Damages Claim Reaches Decision Stage; Klarna Provides Investor Update Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results whi

INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 16:49:00 CET | Press release

New generative AI capabilities, enhanced incident detection, and expanded customer deployments mark a major evolution of the INRIX Traffic product family INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globall

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye